Thus, NaCT and citrate link metabolism to inflammation via IL-6, and targeting SLC13A5 may have therapeutic potential for metabolic disorders, including NAFLD. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.